Precigen (NASDAQ:PGEN) Issues Earnings Results

Precigen (NASDAQ:PGEN) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02, Zacks reports. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%.

Precigen Trading Up 7.2 %

Shares of Precigen stock traded up $0.12 during trading hours on Wednesday, hitting $1.79. 1,382,930 shares of the company were exchanged, compared to its average volume of 1,995,703. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17. The business has a 50-day moving average of $1.57 and a 200-day moving average of $1.14. The stock has a market capitalization of $524.24 million, a price-to-earnings ratio of -3.25 and a beta of 1.58.

Analyst Upgrades and Downgrades

PGEN has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.